Dr. Matt Allerson - Cases Using My PhD In Practice, Putting “Science into Practice”

  • Published on
    14-Apr-2017

  • View
    133

  • Download
    0

Transcript

9/25/20151PuttingScienceintoPracticeUsingmyPhDinpracticeMattAllerson,DVM,PhDHoldenFarms,Inc.9/21/2015Lifelonglearning. B.S.:UWRF(2005) DVM&MPH:UofMN(2009) PhD:UofMN(2013) Current: HoldenFarmsInc.(Northfield,MN) Researchcoordinatorandstaffveterinarian9/25/20152WhyPhD? UofMNVMEDgraduateprogrammission: Fosterdevelopmentofspecificskillsincluding: Experimentalandanalyticalmethods Leadership Communication Independentandcriticalthinking Teaching Interdisciplinaryresearchincollaborativeenvironments ScientificandgrantwritingInfluenzaAvirus Transmissionandcontrolofinfluenzavirusinpigpopulations Weaningagepigs Importanceforinfluenzatransmission SubpopulationforIAVsurveillance9/25/20153InfluenzaAvirusresearchapplication Productionsystemneeds: Multisourcepigflows ClinicalIAVpresentationacrossflows Secondaryinfections Difficultystartingpigs Weaningagepigs Starttofocusonthispopulationtoassessinfluenzavirusprevalenceacrossthesystem SwineHealthMonitoringProject Influenza CurrentlyapilotinitiativeInfluenzaAvirus SystemprevalenceUofMNInfluenzaSHMP,20159/25/20154InfluenzaAvirus SurveillanceUofMNInfluenzaSHMP,2015InfluenzaAvirus ControlUofMNInfluenzaSHMP,20159/25/20155Influenzavirus summary Usingweaningagepigsasoursurveillancepopulation Abilitytoinstitutecontrolmeasuresatthesowfarmlevel Weaningagepigsaveryimportantsubpopulationatthesystemlevel Multisourceflows Movementofpigsacrossmanygeographicreasons Improvethefirstweekonfeedinthenurserystage Goingforward UtilizingvaccinationapproachesthatarebestmatchedtooursowfarmfindingsVaccinetrials ProductAvs.ProductBvs.Nothing? Whataretheoptionstoanswerthesequestions?1. Donothing2. Publishedliterature,CEmeetings,etc.3. Useofcloseoutdata4. Smallscaleresearchfacilities5. Commercialresearchfacilities6. Largescalefieldtrials9/25/20156CommitmenttoresearchVaccinecomparisonsforPCV2 Porcinecircovirustype2(PCVAD) Ubiquitous Difficulttoassessimpactonperformanceinthefielddirectlyacrossfinishinggroups Indirectassessmentthroughvaccinetrials ManycofactorsknowntohaveasignificantroleinPCVAD Theclinicalimpactisgenerallyquiteevident,subclinicalimpact? Canweassessvaccinesinoneresearchsite?9/25/20157PCV2fieldvaccinetrialsSowfarm AllotmenttotreatmentwithinlitterbygenderNursery TreatmentsmixedwithinpenFinisher TreatmentsmixedwithinpenTrial1:5cohortsTrial2:7cohortsPCV2vaccinefieldtrialsTrial1 1,000pigsontestpersite PCV2vaccine(severalcombinations)orcontrol Weight Allotment(weaning) Nurseryexit Priortomarket Mortality9/25/20158PCV2vaccinefieldtrialsTrial2 625pigsontestpersite PCV2vaccine(severalcombinations)orcontrol Weight Allotment(3daysofage) Nurseryexit Priortomarket MortalityDatacollection9/25/20159PCV2example Trial1PCV2example Trial29/25/201510PCV2summary PCV2vaccination Improvedgrowthperformanceandreducedmortality(2x) Subclinicalimpactonunvaccinatedpigshousedwithvaccinatedpigs ReducedperformancewithoutclinicalexpressionofPCVAD Variabilityofdisease/pathogenexposure Shouldweexpectthisvariabilitywithotherpathogens?Puttingscienceintopractice Newandemergingpathogenswillcontinuetochallengeus: PRRSv PCV2 2009PandemicIAV PEDv SVV Sciencebasedpracticewillcontinuetoleadourindustryintherightdirection9/25/201511Questions?Thankyou